Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026)

Jazz Pharmaceuticals' Receivables history runs 17 years deep, the most recent figure standing at $836.3 million for Q1 2026.

• In Q1 2026, Receivables rose 28.07% year-over-year to $836.3 million; the TTM figure through Mar 2026 stood at $836.3 million (up 28.07% YoY), while the FY2025 annual figure was $830.7 million, up 15.9% from the prior year.
• Receivables for Q1 2026 stood at $836.3 million, up from $830.7 million in the prior quarter.
• The five-year high for Receivables was $836.3 million in Q1 2026, with the low at $572.4 million in Q1 2022.
• The 5-year median for Receivables is $698.0 million (2024), against an average of $684.2 million.
• The sharpest annual moves came in 2022 and 2025: Receivables surged 38.27% in 2022, then retreated 7.65% in 2025.
• Jazz Pharmaceuticals' Receivables stood at $651.5 million in 2022, then advanced by 8.33% to $705.8 million in 2023, then gained by 1.55% to $716.8 million in 2024, then advanced by 15.9% to $830.7 million in 2025, then gained by 0.67% to $836.3 million in 2026.
• Business Quant data shows JAZZ's Receivables at $836.3 million in Q1 2026, $830.7 million in Q4 2025, and $764.4 million in Q3 2025.